Maternal thyroid function and the outcome of external cephalic version: a prospective cohort study

Kuppens et al.
Maternal thyroid function and the outcome of external cephalic version: a prospective cohort study

Simone M Kuppens1,2*, Libbe Kooistra3, Tom H Hasaart2, Riet W van der Donk2, Huib L Vader4,5, Guid S Oei6,7, Victor J Pop1

Abstract

Background: To investigate the relation between maternal thyroid function and the outcome of external cephalic version (ECV) in breech presentation.

Methods: Prospective cohort study in 141 women (≥ 35 weeks gestation) with a singleton fetus in breech. Blood samples for assessing thyroid function were taken prior to ECV. Main outcome measure was the relation between maternal thyroid function and ECV outcome indicated by post ECV ultrasound.

Results: ECV success rate was 77/141 (55%), 41/48 (85%) in multipara and 36/93 (39%) in primipara. Women with a failed ECV attempt had significantly higher TSH concentrations than women with a successful ECV (p < 0.001). Multiple logistic regression showed that TSH (OR: 0.52, 95% CI: 0.30-0.90), nulliparity (OR: 0.11, 95% CI: 0.03-0.36), frank breech (OR: 0.30, 95% CI: 0.10-0.93) and placenta anterior (OR: 0.31, 95% CI: 0.11-0.85) were independently related to ECV success.

Conclusions: Higher TSH levels increase the risk of ECV failure.

Trial registration number: ClinicalTrials.gov: NCT00516555

Background

The incidence of breech presentation decreases with increasing gestational age from approximately 16% at 32 weeks to 3-5% of all pregnancies at term [1]. External cephalic version (ECV) is recommended by the American College of Obstetricians and Gynecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) as the best method to reduce the number of breech presentations and breech deliveries at term [2,3]. Also the Dutch Obstetrics & Gynaecology Society has promoted ECV but up until now, the implementation of this guideline is rather poor and a recent study has been started to evaluate possible barriers [4]. Reported success rates vary widely from 30-80% [3]. Several factors have been associated with successful ECV outcome including parity, type of breech, placenta location, amniotic fluid index, and engagement of the breech [5-7].

Recently, our research group showed that at 36 weeks gestation women with TSH levels above 2.5 mIU/l are at risk for breech presentation [8,9]. It is stated that fetal movements and mobility are a prerequisite for spontaneous version into the cephalic position [10]. Since maternal thyroid function is related to the probability of spontaneous cephalic presentation, it may be hypothesized that TSH may, also, affect ECV outcome [8,9].

To the best of our knowledge, this is the first prospective study to examine the relationship between maternal thyroid hormone status and ECV success.

Methods

Participants

Over a period of two years, 194 women were prospectively seen in a specialized ECV outpatient clinic and invited to participate when they presented at ≥ 35 weeks gestation with a fetus in breech presentation.
Only Caucasian patients with sufficient knowledge of the Dutch language were eligible (n = 169). Nineteen patients declined to participate, while four patients with a transverse lie and five patients with known thyroid disease were excluded. Data analysis, therefore, included the remaining 141 participants (see Table 1), all of whom gave written informed consent.

Table 1 Characteristics and thyroid parameters of 141 breech women who had an ECV attempt

| Characteristics                      | Mean (SD) | N (%) |
|--------------------------------------|-----------|-------|
| **Demographic features**             |           |       |
| Maternal age (years)                 | 31.6 (4.2)|       |
| Range (23 - 46)                      |           |       |
| Any tobacco use                      | 11 (8)    |       |
| Any alcohol use                      | 12 (8.5)  |       |
| Body mass index (BMI)                |           |       |
| Range (17 - 47)                      | 23.7 (4.2)|       |
| BMI < 25                             | 112 (79.5)|       |
| BMI between 25 and 30                | 17 (12)   |       |
| BMI > 30                             | 12 (8.5)  |       |
| Previous miscarriage in life         | 31 (22)   |       |
| **Obstetrical features**             |           |       |
| Nulliparity                          | 93 (66)   |       |
| Multiparity                          | 48 (34)   |       |
| Gestational age at ECV (wks)         | 36.1 (0.9)|       |
| Range (35.0-39.9)                    |           |       |
| **Type of breech**                   |           |       |
| Frank                                | 93 (66)   |       |
| Complete                             | 36 (25.5) |       |
| Incomplete                           | 12 (8.5)  |       |
| **Placenta location**                |           |       |
| Anterior                             | 55 (39)   |       |
| Posterior                            | 56 (40)   |       |
| Lateral                              | 30 (21)   |       |
| Cephalic presentation after ECV      | 77 (55)   |       |
| Cephalic presentation at delivery    | 79 (56)   |       |
| Placental weight (grams)             | 615 (127) |       |
| Range (295 - 1000)                   |           |       |
| Birth weight (grams)                 | 3344 (447)|       |
| Range (1765 - 4576)                  |           |       |
| **Thyroid parameters**               |           |       |
| TSH mIU/l                            | 1.48      |       |
| Range (0.02 - 10.0)                  |           |       |
| FT4 pmol/l                           | 10.0      |       |
| Range (7.1 - 14.0)                   |           |       |
| TPO-Ab > 35 kU/l                     | 9 (6)     |       |

This study was approved by the Medical Ethical Committee of the Catharina Hospital in Eindhoven, the Netherlands.

Assessments
At intake, demographic features (maternal age, BMI, tobacco/alcohol use) and obstetrical parameters (parity, previous obstetrical history) were recorded. Prior to ECV, ultrasound was performed to determine type of breech, amniotic fluid index and placental location. Ultrasound was repeated post-ECV in order to confirm success. At birth, fetal presentation, placental and birth weight were carefully assessed.

ECV intervention
Cardiotocography was performed routinely before and after the procedure. Before ECV, all women had a full bladder and were routinely given a tocolytic drug (Atosiban, 6.75 mg. intravenously). Anti-D (1000 IE) was given prophylactically to all Rhesus negative women. ECV (monitored by ongoing ultrasound) was performed by two experienced obstetricians working in unison: the hands of one staff member concentrated on the breech, while the other’s concentrated on the fetal head, with manipulation being consecutive rather than simultaneous (see Additional file 1). While a “forward somersault” was the preferred method to achieve cephalic position, a “backward flip” was an alternative strategy for nulliparous patients with a frank breech presentation. ECV was defined as successful when cephalic position was demonstrated on the post-ECV ultrasound.

Thyroid parameters
Blood samples were taken prior to administration of the tocolytic drug and subsequently stored for assessing the following thyroid parameters: thyroxine (FT4), thyroid-stimulating hormone (TSH) and thyroid peroxidase antibodies (TPO-Ab). TSH was measured using a solid-phase, two-site chemiluminescent enzyme immunoassay (IMMULITE Third generation TSH, Diagnostic Products Corporation, Los Angeles USA). The inter-assay coefficients of variation were 5.0% and 4.4% at concentrations 0.22 mIU/l and 2.9 mIU/l, respectively. FT4 concentration was also measured by means of a solid-phase immunometric assay (IMMULITE Free T4). The inter-assay coefficients of variation for this technique were 6.7% and 4.4% at concentrations of 11.6 pmol/l and 31.5 pmol/l, respectively. Reference ranges for non-pregnant women for TSH and FT4 were: 0.4 - 4.0 mIU/l and 10 - 24 pmol/l, respectively. The IMMULITE TPO-Ab kit was used for the determination of antibodies against thyroid peroxidase (TPO). The inter-assay coefficients of variation for this analysis were 9% and 9.5% for concentrations of 40 kU/l
and 526 kU/l, respectively. The anti-TPO assay was standardized in terms of the International Reference Preparation for anti-TPO MRC 66/387. TPO-Ab concentrations > 35 kU/l at 36 weeks gestation were regarded as antibody positive.

Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS 17.0). Initial analyses described the sample using means, standard deviations and frequencies. The distributions of FT4 and TSH were non-Gaussian (Kolmogorov-Smirnov tests); therefore, Mann-Whitney U-tests were used to examine FT4 and TSH for group comparisons and ECV success. Associations among elevated maternal thyroid antibodies (TPO-Ab > 35 kU/l) and ECV outcome were analyzed using chi-square tests. Prevalence of successful ECV stratified according to quartiles of TSH was also examined using a chi-square test. Single and multiple logistic regression analysis (odds ratios and 95% CI’s) were performed to calculate un-adjusted and adjusted ORs for successful ECV (dependent variable). The independent variable was TSH. For the multiple logistic regression analysis, age (continuous), body mass index (continuous), parity (dichotomized in nulliparous and parous), type of breech (frank breech versus the rest), gestational age at version (continuous), placental position (dichotomized in anterior versus other), placental weight (continuous), birth weight (continuous) and amniotic fluid index (dichotomized using 10 cm as a cutoff) were also controlled for.

Results
The overall ECV success rate, indicated by the post-procedure ultrasound results, was 55% (77/141), and was significantly lower in nulliparous women (39%: 36/93) than in multiparous women (85%: 41/48; $\chi^2 = 27$, df = 1, $p < 0.001$). In one patient prolonged post-ECV fetal bradycardia occurred which necessitated emergency cesarean section. Transient heart rate abnormalities were observed in 3 patients. Spontaneous version into cephalic position at birth after failed ECV occurred in 2 (nulliparous) women. Spontaneous version back into breech after successful ECV did not occur.

The median TSH level for the whole study sample was 1.48 mIU/l (range: 0.02 - 10 mIU/l). Table 2 shows the distribution of FT4 and TSH values in relation to ECV outcome. Women with failed ECV’s had significantly higher TSH levels than those with successful ECV’s (Mann-Whitney U, $p < 0.001$), but corresponding FT4 levels did not differ between groups (Mann-Whitney U, $p = 0.88$). The correlation between FT4 and TSH was 0.18, ($p = 0.034$). Also, the prevalence of elevated TPO-Ab (> 35 kU/l) did not differ between groups (9% versus 4%, $p = 0.18$) with regard to ECV outcome.

Figure 1 shows the prevalence of successful ECV according to different TSH quartiles (25th percentile: < 0.99 mIU/l, 25th - 50th percentile: 0.99 - 1.48 mIU/l, 50th - 75th percentile: 1.49 - 2.0 mIU/l and > 75th percentile: > 2.0 mIU/l). Clearly, the percentage of ECV success significantly decreased with increasing TSH quartile (74% to 30%, $\chi^2 = 15$, df = 3, $p = 0.002$).

In Table 3, single logistic regression is shown with successful ECV as the dependent variable. TSH, parity, type of breech and placenta anterior location were all significantly related to successful ECV outcome. In Table 3, adjusted OR’s are shown with TSH as independent variable and successful ECV as dependent variable using multiple logistic regression analysis. TSH (OR: 0.52, 95% CI: 0.30-0.90), nulliparity (OR: 0.11, 95% CI: 0.03-0.36), frank breech (OR: 0.30, 95% CI: 0.10-0.93) and placenta anterior (OR: 0.31, 95% CI: 0.11-0.85) were all significantly and independently related to ECV success.

In healthy pregnant women (without elevated concentrations of TPO-Ab and with proven sufficient iodine intake) trimester specific cutoffs for elevated TSH are still lacking. A frequently used upper TSH reference level in pregnancy is ≥ 2.5 mIU/l [11]. In the current study 20 women had a TSH above this level. Of these 20 women 5 (25%) underwent successful ECV, compared to 72 successful ECVs from the sample of 121 women (60%) with TSH levels below the cutoff of 2.5 mIU/l ($\chi^2 = 8.2$, df = 1, $p = 0.004$). The RR of women in breech with TSH above 2.5 mIU/l for failed ECV was 2.4, (95% CI = 1.1 - 5.3).

Discussion
In the current study, successful ECV outcome was independently related to maternal TSH: women with unsuccessful ECV had significantly higher TSH levels.

The ECV success rate of 55% in the current study is comparable to others reported in the literature [2,3]. While our data support earlier observations showing that factors affecting ECV success include parity, type of breech and placenta location, to our knowledge, this is the first study reporting on a possible relationship between maternal thyroid function and ECV outcome [5-7].

We recently showed in a large sample of over 1000 pregnant women from the general population that higher levels of TSH constitutes a risk factor for breech presentation [8].

How can the observed relationship between maternal TSH and ECV outcome be explained? Several mechanisms might be suggested. First, one could argue that
elevated maternal TSH directly impacts uterine relaxation, thereby negatively affecting ECV outcome. Empirical evidence regarding such a direct effect is, however, scarce. TSH receptors have been shown in other non-thyroid tissues such as bone, heart and brain tissue, but so far no studies on human uterine samples have been published [12,13]. Also, in patients with subclinical hypothyroidism (reflected by high TSH), the myocytes of the smooth muscle cells of the aorta are dysfunctional, leading to increased arterial stiffness and impaired diastolic function [14]. The mechanism behind is a reduced activity of the sarcoplasmatic reticulum CA-ATPase which controls the efficient concentration of calcium in the cytoplasm. Another study in subclinical hypothyroid women showed a beneficial effect of thyroxine replacement on arterial stiffness [15]. It is known from earlier studies that thyroid hormone (T3) has a direct relaxation effect on vascular smooth muscle cells [16]. It might be hypothesized that a similar relation between TSH and uterine myocytes does exist. Inappropriate relaxation of uterine smooth muscle vessels in women with high TSH might hinder ECV. Another candidate mechanism might relate to fetal motility and its ability to facilitate spontaneous version. High maternal TSH during gestation has been associated with impaired neonatal motor function [17]. One may argue that higher levels of maternal TSH could conceivably reflect low circulating fetal T4 levels. Shortage of fetal T4 compromises fetal neural maturation and, in turn, fetal motility through its effects on muscle tone and reflexes [18]. Furthermore, breech babies tend to be smaller, have lower scores on neuromotor tests, and are balanced-impaired until the age of 12-18 months [19-22]. Their impaired neuromotor development could

| Table 2 Thyroid parameters in 141 breech women in relation to ECV outcome |
|-----------------------------------------------|-----------------------------------------------|
| Success ECV N = 77                           | Failed ECV N = 64                            |
| Median TSH mIU/l 1.20                        | 1.90                                         | < 0.001|
| Range 0.02-10.0                              | 0.60-9.20                                    |
| Median FT4 pmol/l 10.0                       | 10.0                                         | 0.88    |
| Range 7.2-14.0                               | 7.1-14.2                                     |
| TPO-Ab > 35 kIU/l 3 (4%)                     | 6 (9%)                                       | 0.18    |

Figure 1 Percentage of ECV success in relation to TSH quartiles (mIU/l) in 141 women with breech presentation ≥ 35 weeks gestation
Conclusions

In conclusion, the current study is among the first to report a possible relationship between maternal thyroid function and ECV outcome. While the study suggests that higher levels of TSH are independently related to ECV outcome, the precise mechanism behind this finding remains to be determined.

Additional material

Additional file 1: ECV technique. ECV is performed by two experienced obstetricians working closely together: the hands of one obstetrician concentrate on the breech, while the other’s concentrate on the fetal head, with manipulation being consecutive rather than simultaneous and changing from a “pull” movement into a “push” movement. The procedure is monitored by a third person by ongoing ultrasound.

Acknowledgements

We wish to acknowledge the support of the Scientific Foundation of the Catharina Hospital.

Author details

1Department of Primary Care, University of Tilburg, Tilburg, the Netherlands. 2Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, the Netherlands. 3Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Canada. 4Department of Clinical Chemistry, Máxima Medical Centre, Veldhoven, the Netherlands. 5Department of Biomedical Engineering, University of Technology, Eindhoven, the Netherlands. 6Department of Obstetrics and Gynecology, Máxima Medical Centre, Veldhoven, the Netherlands. 7Department of Electrical Engineering, University of Technology, Eindhoven, the Netherlands.

Authors’ contributions

SK, RD, TH and VP were involved in conception and design of the study. SK, HV and VP drafted the first manuscript. SK, RD, TH and VP were involved in conception and design of the study. SK, HV and VP performed data analysis. SK, RD, TH and VP were involved in conception and design of the study. SK, HV and VP were involved in conception and design of the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 30 August 2010 Accepted: 26 January 2011

Published: 26 January 2011

References

1. Hill LM. Prevalence of breech presentation by gestational age. Am J Perinatol 1990, 7:92-93.
2. American College of Obstetrician and Gynecologists: External cephalic version. ACOG Practice Bulletin 13 Washington, DC:ACOG, 2000.
3. Royal College of Obstetricians and Gynecologists: External cephalic version and reducing the incidence of breech presentation. Guideline 2006. Royal College of Obstetricians and Gynaecologists 2006.
4. Vlemmix F, Rosman AN, Fleuren MA, et al: Implementation of the external cephalic version in breech delivery. Dutch national implementation study of external cephalic version. BMC Pregnancy Childbirth 2010, 10(10):20.

5. Kol M, Crossen J, Gravenedel L, van der Post JA, Opmeer B, Mol BW: Clinical factors to predict the outcome of external cephalic version: a meta-analysis. Am J Obstet Gynecol 2008, 199:630-37.

6. Kol M, Crossen J, Gravenedel L, Van Der Post JA, Mol BW: Ultrasound factors to predict the outcome of external cephalic version: a meta-analysis. Ultrasound Obstet Gynecol 2009, 33:76-84.

7. Ben-Arie A, Erez Y, Sela HY, Shevky D, Tufir A, Ezra Y: Prognostic parameters for successful external cephalic version. J Matern Fetal Neonatal Med 2008, 21:660-62.

8. Kuppens SM, Kooistra L, Wijnen HA, Crawford S, Vader HL, Hasaart TH, Oei SG, Pop VJ: Maternal thyroid function during gestation is related to breech presentation at term. Clin Endocrinol (Oxf) 2010, 72:820-4.

9. Kooistra L, Kuppens SM, Hasaart TH, Vader HL, Wijnen HA, Oei SG, Pop VJ: High thyrotrophin levels at end term increase the risk of breech presentation. Clin Endocrinol (Oxf) 2010.

10. Witkop CT, Zhang J, Sun W, Troendle J: High thyrotrophin levels at end term increase the risk of breech presentation. Clin Endocrinol (Oxf) 2010.

11. Abalovich M, Amino N, Barbou LA, Cobin RH, De Groot LJ, Ginoar D, Mandel SJ, Stagner-Green A: Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2007, 92:51-47.

12. Peeters RP, van der Deure WM, Visser TJ: Genetic variation in thyroid hormone pathway genes: polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur J Endocrinol 2006, 155:655-62.

13. Heemstra KA, van der Deure WM, Peeters RP, Hamdy NA, Stokkel MP, Corssmit EP, Ramin J, Visser TJ, Smit JW: Thyroid hormone independent associations between serum TSH levels and indicators of bone turnover in cured patients with differentiated thyroid carcinoma. Eur J Endocrinol 2008, 159:69-76.

14. Pap G, Uberti ED, Betterle C, Carani C, Pearce EN, Braverman LE, Roti E: Subclinical hypothyroidism: editorial. Curr Opin Endocrinol Diabetes Obes 2007, 14:197-208.

15. Owen P, Rajv C, Vinereanu D, Mathew T, Fraser AG, Lazarus JH: Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab 2006, 91:2126-32.

16. Ojamaa K, Klemperer JD, Klein I: Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996, 6:505-12.

17. Williams GR: Neurodevelopmental and neurophysiological actions of thyroid hormone. J Neuroendocrinol 2008, 20:784-94.

18. Wijnen HA, Kooistra L, Vader HL, Essed GG, Mol BW, Pop VJ: Maternal thyroid hormone concentration during late gestation is associated with foetal position at birth. Clin Endocrinol (Oxf) 2009, 71:46-51.

19. Luterkort M, Polberger S, Persson PH, Bjorlie I: Role of asphyxia and slow intrauterine growth in morbidity among breech delivered infants. Early Hum Dev 1986, 14:19-31.

20. Kean LH, Suwanrath C, Gargari SS, Sahota DS, James DK: A comparison of fetal behaviour in breech and cephalic presentations at term. Br J Obstet Gynaecol 1999, 106:1209-13.

21. Molkema SR, Roumen FJ, Smit JS, Nijhuis KJ: Birth weight and neurodevelopmental outcome of children at 2 years of age after planned vaginal delivery for breech presentation at term. Am J Obstet Gynecol 2006, 194:624-29.

22. Sival DA, Prechtl HF, Sontheim GH, Touwen BC: The effect of intra-uterine breech position on postnatal motor functions of the lower limbs. Hum Dev 1995, 32:161-76.

23. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ: Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J of Endocrinol 2009, 160:985-991.

24. Lee RH, Spencer EA, Mestman JH, Miller EA, Petrovic I, Braverman LE, Goodwin TM: Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol 2000, 183:86-91.

25. Newman RB, Peacock BS, VanDorsten JP, Hunt HH: Predicting success of external cephalic version. Am J Obstet Gynecol 1993, 169:245-49.

26. Lau TK, Lo KW, Wan D, Rogers MS: Predictors of successful external cephalic version at term: a prospective study. Br J Obstet Gynaecol 1997, 104:798-802.

27. Wong WM, Lao TT, Liu KL: Predicting the success of external cephalic version with a scoring system. A prospective, two-phase study. J Reprod Med 2000, 45:201-6.

28. Chan LY, Leung TY, Fok WY, Chan LW, Lau TK: Prediction of successful vaginal delivery in women undergoing external cephalic version at term for breech presentation. Eur J Obstet Gynecol Reprod Biol 2004, 116:39-42.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2393/11/10/prepub

Cite this article as: Kuppens et al: Maternal thyroid function and the outcome of external cephalic version: a prospective cohort study. BMC Pregnancy and Childbirth 2011 11:10.